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EchocardiographyAims: Percutaneous mitral balloon valvotomy PMBV is an acceptable alternative to Mitral valve surgery
for patients with mitral stenosis. The purpose of this study was to explore the immediate results of PMBV
with respect to echocardiographic changes, outcomes, and complications, using a meta-analysis
approach.
Methods: MEDLINE, and EMBASE databases were searched (01/2012 to 10/2018) for original research
articles regarding the efficacy and safety of PMBV. Two reviewers independently screened references
for inclusion and abstracted data including article details and echocardiographic parameters before
and 24–72 h after PMBV, follow-up duration, and acute complications. Disagreements were resolved
by third adjudicator. Quality of all included studies was evaluated using the Newcastle-Ottawa Scale NOS.
Results: 44/990 references met the inclusion criteria representing 6537 patients. Our findings suggest
that PMBV leads to a significant increase in MVA (MD = 0.81 cm2; 0.76–0.87, p < 0.00001), LVEDP
(MD = 1.89 mmHg; 0.52–3.26, p = 0.007), LVEDV EDV (MD = 5.81 ml; 2.65–8.97, p = 0.0003) and decrease
in MPG (MD = 7.96 mmHg; 8.73 to 7.20, p < 0.00001), LAP (MD = 10.09 mmHg; 11.06 to 9.12,
p < 0.00001), and SPAP (MD = 15.55 mmHg; 17.92 to 13.18, p < 0.00001). On short term basis, the
pooled overall incidence estimates of repeat PMBV, mitral valve surgery, post-PMBV severe MR, and post-
PMBV stroke, and systemic thromboembolism were 0.5%, 2%, 1.4%, 0.4%, and 0.7% respectively. On long
term basis, the pooled overall incidence estimates of repeat PMBV, mitral valve surgery, post-PMBV sev-
ere MR, and post-PMBV stroke, systemic thromboembolism were 5%, 11.5%, 5.5%, 2.7%, and 1.7% respec-
tively
Conclusion: PMBV represents a successful approach for patients with mitral stenosis as evidenced by
improvement in echocardiographic parameters and low rate of complications.
 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mitral stenosis (MS) is a disabling disease that limits the normal
physical abilities of patients and considered as a major reason for
hospital admissions [1]. The leading cause of MS globally is rheu-
matic heart disease RHD which remains common in economically
developing countries and continues to be a significant cause of
morbidity and mortality. Other less common causes of growing
importance include mitral annular calcification typically seen in
older adults, patients with advanced kidney disease, or survivors
of mantle irradiation [3]. MS patients usually present with
A.A. Abu Rmilah, M.A. Tahboub, A.K. Alkurashi et al. IJC Heart & Vasculature 33 (2021) 100765exertional dyspnea and increased fatigue which are mainly related
to the severity of stenosis [2]. Symptomatic severe MS also called
stage D is defined as a mitral valve area 1.5 cm2 and diastolic
pressure half-time 150 ms [2,3]. Rheumatic mitral valve changes
are present along with severe left atrial enlargement and pul-
monary artery systolic pressure > 30 mmHg [3]. For many years,
the prime course of MS management was through open heart sur-
gery. This was the trend until 1984–1985 when Inoue and Lock
developed an alternative minimally invasive procedure called per-
cutaneous mitral balloon valvotomy (PMBV) [4]. MS is a mechani-
cal disorder that its mortality is only improved by PMBV or
surgery. Medications can treat the symptoms but do not treat the
principle cause of the disease [5,6].
According to the AHA/ACC guideline, PMBV is indicated for
patients with severe MS whom valve morphology is pliable and
non-calcified with no left atrial thrombus whether they are symp-
tomatic or not [7].
Numerous observational, small case series and prospective tri-
als are available in the literature for analysis of outcomes and com-
plications. The purpose of this study was to examine the
immediate results of PMBV with respect to echocardiographic
changes, outcomes, and complications, using a meta-analysis
approach.2. Materials and methods
This review was completed in accordance with PRISMA stan-
dards for systemic review and meta-analysis quality reporting
(http://www.prisma-statement.org/).
2.1. Study eligibility
We included all original controlled trials or observational
research studies published between 01/01/2012 and 10/19/2018
pertaining to the efficacy and safety of percutaneous mitral balloon
valvotomy, valvuloplasty or commissurotomy in patients older
than 18 years with severe mitral stenosis regardless of their gen-
der. We included all studies aimed to analyze the impact of PMBV
in MS patients by reporting the mean values with standard devia-
tions of echocardiographic and hemodynamic parameters before
and after the procedure. Our exclusion criteria included basic
science/animal studies, conference abstracts, case reports, non-
original research (e.g. editorials, commentaries), and pregnant or
pediatric studies, studies involving patients receiving redo PMBV
or open mitral valve surgery, and patients with left atrial throm-
bus, unfavorable mitral valve morphology, and need for cardiac
surgery because of severe aortic, tricuspid, or coronary disease
2.2. Search strategy and information sources
A professional librarian (PJE) performed (with subject-matter
experts’ input) our thorough search strategy in 01/01/2019 using
MEDLINE, and Embase databases. The following keywords were
used to perform the literature search, (transcatheter OR percuta-
neous OR endovascular OR balloon OR cardiac catheterization OR
valvuloplasty OR valvotomy OR commissurotomy OR annulo-
plasty) and (mitral valve OR mitral valve stenosis). See Appendix
1 for full search details.
2.3. Study selection
The selection of studies was independently executed in dupli-
cate by two trained reviewers (AA, JS) and coordinated using Cov-
idence systematic review software (Veritas Health Innovation,
Melbourne, Australia). Initially, reviewers screened the retrieved2
articles by title and abstract for preliminary relevance. Thereafter,
a full text screening was performed for all potential relevant stud-
ies for final inclusion. Authors were contacted as needed for further
information if possible. Studies with incomplete information after
author contact were excluded. Any eligibility conflicts were
resolved by consensus with a third reviewer (RG). A kappa statistic
was calculated to assess the agreement [8]. A PRISMA-style flow
diagram was illustrated in Fig. 1.2.4. Data collection
Two reviewers (AA, JS or AD) working independently and in
duplicate abstracted information on study details, baseline patient
demographics, echocardiographic parameters before and after
PMBV, follow-up duration, and acute complications of PMBV such
as severe mitral regurgitation, repeat PMBV, the need of mitral
valve surgery, systemic thromboembolism, stroke, atrial fibrilla-
tion, cardiac tamponade and mortality2.5. Quality assessment
Quality of all included studies was evaluated with the
Newcastle-Ottawa Scale NOS [9] by two reviewers (AA, JS or AD)
working independently. A third reviewer (RG) resolved any dis-
agreements. The checklist form for cohort studies of NOS was con-
sidered for our assessment. Studies were then classified into one of
three categories, a) good quality 7–8 points b) fair quality 3–6
points and c) poor quality 0–2 points.2.6. Synthesis of results and statistical analysis
We designed two standardized spread sheet tables for data
extraction, one for baseline patient characteristics and one for
echocardiographic parameters and adverse events of PMBV. Con-
tinuous variables were represented as means and standard devia-
tions (SD), whereas categorical variables were expressed as
number of cases (n) and percentages (%). We quantitatively pooled
using a weighted average of the effects from unique studies and
analyzed the results via fixed effect or random effect model, based
on whether the absence of significant heterogeneity was present
using Review Manager statistical software (RevMan 5.3; Copen-
hagen, Denmark) [10] and Open Meta-Analyst software (Brown
University, Rhode Island, USA). If the absence of heterogeneity
was significant, the fixed effect model (Mantel-Haenszel test)
was performed, but if not, the random effect model
(DerSimonian-Laird method) was used. For continuous data, the
weighted summary mean difference (MDs) along with 95% confi-
dence intervals (CIs) was calculated using the inverse-variance
test. For dichotomous data, individual study incidence rate esti-
mates underwent logit transformation to calculate the weighted
summary proportion along with 95% confidence intervals (CIs)
under the random effect model (DerSimonian-Laird method). Sta-
tistical significance was defined as p-value of <0.05. Statistical
heterogeneity was assessed using the Cochran’s Q test and quanti-
fied using the I2 statistic; significant heterogeneity was defined as
p-value < 0.1 and I2 > 50%. Publication bias was represented graph-
ically by funnel plots; absence of publication bias was defined
when all studies (dots) exist within the funnel in a symmetrical
manner.
Fig. 1. PRISMA-style flow diagram for a systematic review and meta-analysis of PMBV for severe MS patients.
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3.1. Study characteristics
We identified 990 references from electronic databases using
the previously described strategy. According to the inclusion crite-
ria, 81 citations were retrieved and required further evaluation
using the full text version after screening the title and abstract.
Thirty seven studies were excluded due to the following reasons,
Absence of echocardiographic parameters before and after PMBV
in thirty-one studies, insufficient abstract without full text version
in 2 studies, pediatric population in one study, non-original
research work in 4 studies; 2 reviews and 1 commentary and 1 edi-
torial. Consequently, 44 studies (6537 enrolled patients) were
selected for this meta-analysis. The kappa statistic for initial
screening for inclusion was 0.73, indicating substantial agreement.
The selection process is demonstrated in a flow chart (Fig. 1). The
main features and patient demographics of all included studies
are mentioned in Table 1.
3.2. Quality assessment
Overall, the majority of included studies were judged to be fair
quality, with most receiving three or more stars by Newcastle-
Ottawa scale. (Supplementary Table)
3.3. Quantitative data synthesis
In the present analysis, we are highlighting the clinical impact
of PMBV on the following echocardiographic measurements, a)
mitral related variables (mitral valve area MVA, mitral pressure
gradient MPG), b) left atrial variables (left atrial diameter LAD, left
atrial pressure LAP), c) left ventricular variables (left ventricular
end-diastolic volume, LV EDV, left ventricular end-diastolic pres-3
sure LV EDP, left ventricular end-systolic volume LV ESV and left
ventricular end-systolic volume LV ESP), and d) systolic pulmonary
arterial pressure SPAP. These measurements were taken before and
within 24–72 h following PMBV and changes over this duration
reflect the immediate echocardiographic efficacy of PMBV. Further-
more, the incidence of the main adverse events including severe
MR, repeat PMBV, the need of mitral valve surgery, systemic
thromboembolism, stroke, atrial fibrillation, cardiac tamponade
and mortality occurring on short (<30 days) and long term (>6
months) basis after PMBV was described in this section.
3.3.1. Effect of PMBV on mean mitral valve area (MVA in cm2)
A total of 37 studies provided data for the meta-analysis for
MVA change (5572 participants) before and after PMBV. The over-
all results of random effect model showed that PMBV does lead to a
significant increase in MVA levels (MD = 0.81 cm2, 95% CI = 0.76 to
0.87, p = 0 < 0.00001) (Fig. 2). There was heterogeneity across stud-
ies for MVA changes (I2 = 97%, p < 0.00001).
3.3.2. Effect of PMBV on mean trans-mitral pressure gradient (MPG in
mmHg)
Thirty one of included studies representing 5223 patients
reported MPG scores before and after PMBV. Overall,
meta-analysis results of the random effect model showed a signif-
icant reduction in MPG levels compared to pre-PMBV levels as
shown in Fig. 3 (MD = -7.96 mmHg, 95% CI = 8.73 to 7.20,
p < 0.00001). There was heterogeneity across studies for MPG
changes (I2 = 96%, p < 0.00001).
3.3.3. Effect of PMBV on mean systolic pulmonary artery pressure
(SPAP in mmHg)
Twenty four studies were included in the meta-analysis to esti-
mate the pooled changes in SPAP after PMBV as compared with
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Fig. 2. . Meta-analysis of 37 studies reporting MVA changes before and after PMBV in 5572 MS patients.
A.A. Abu Rmilah, M.A. Tahboub, A.K. Alkurashi et al. IJC Heart & Vasculature 33 (2021) 100765remarkable significant decrease in SPAP levels compared to pre-
PMBV levels as illustrated in Fig. 4 (MD = 15.55 mmHg, 95%
CI = 17.92 to 13.18, p < 0.00001). There was heterogeneity
across studies for MPG changes (I2 = 94%, p < 0.00001).3.3.4. Effect of PMBV on mean left atrial diameter (LAD in mm) and
pressure (LAP in mmHg)
A total of 16 and 14 studies provided data for the meta-analysis
for LAD (991 participants) and LAP (2056 participants) changes
respectively. The overall results of random effect model showed
that PMBV leads to a significant decline in the levels of LAD
(MD = 3.23 mmHg, 95% CI = 3.77 to 2.69, p < 0.00001) and
LAP (MD = 10.09 mmHg, 95% CI = 11.06 to 9.12,
p < 0.00001) (Supplementary Figs. 1, 2). There was mild hetero-
geneity across studies for LAD changes (I2 = 23%, p = 0.18), whereas
substantial heterogeneity was found across studies for LAP changes
(I2 = 87%, p < 0.00001).3.3.5. Effect of PMBV on mean left ventricle volume (in ml) and
pressure (in mmHg)
We included four and five studies for meta-analysis of changes
in LV EDV (142 participants) and EDP (475 participants) respec-
tively. PMBV has led to significant increase in LV EDV
(MD = 5.81 ml, 95% CI = 2.65–8.97, p = 0.0003), and EDP (MD = 1
.89 mmHg, 95% CI = 0.52–3.26, p = 0.007) (Supplementary Figs. 3,
4). There was a strong homogeneity among studies reporting LV
EDV changes (I2 = 0%, p = 0.39), whereas heterogeneity was found
among studies reporting LV EDP changes (I2 = 93%, p < 0.00001). No
significant differences were found in the levels of LV ESV and ESP6
before and after PMBV (p value for ESV = 0.12, p value for
ESP = 0.24).3.3.6. Main Adverse events following PMBV
The pooled overall incidence estimate of severe MR following
PMBV was 1.4% (I2 = 83.88%, p < 0.001) among 3759 patients in
14 studies on short term duration and 5.5% (I2 = 82.93%,
p < 0.001) among 1182 in 5 studies on long term duration (Supple-
mentary Fig. 5). The pooled overall incidence estimate of repeat
PMBV was 0.5% (I2 = 83.88%, p < 0.001) among 357 patients in 4
studies on short term duration and 5% (I2 = 89.49%, p < 0.001)
among 3962 in 13 studies on long term duration (Supplementary
Fig. 6). The pooled overall incidence estimate of the need for mitral
valve surgery following PMBV was 2% (I2 = 68.28%, p < 0.001)
among 3829 patients in 11 studies on short term duration and
11.5% (I2 = 93.52%, p < 0.001) among 3862 in 13 studies on long
term duration (Supplementary Fig. 7). The pooled overall incidence
estimate of stroke following PMBV was 0.4% (I2 = 0%, p = 0.463)
among 1570 patients in 5 studies on short term duration and
2.7% (I2 = 60.02%, p = 0.014) among 2695 in 8 studies on long term
duration (Supplementary Fig. 8). The pooled overall incidence esti-
mate of systemic thromboembolism following PMBV was 0.7%
(I2 = 71.33%, p = 0.002) among 2759 patients in 7 studies and
1.7% (I2 = 0%, p = 0.497) among 1157 in 3 studies (Supplementary
Fig. 9). The pooled overall incidence estimate of atrial fibrillation
following PMBV was 4.1% (I2 = 0%, p = 0.849) among 120 patients
in 2 studies on short term duration 5.1% (I2 = 0%, p = 0.402) among
324 in 3 studies on long term duration (Supplementary Fig. 10).
The pooled overall incidence estimate of cardiac tamponade on
Fig. 3. Meta-analysis of 31 studies reporting MPG changes before and after PMBV in 5223 MS patients.
Fig. 4. Meta-analysis of 24 studies reporting SPAP changes before and after PMBV in 4146 MS patients.
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among 3066 patients in 7 studies (Supplementary Fig. 11). The
pooled overall incidence estimate of mortality following PMBV
was 0.2% (I2 = 0%, p = 0.879) among 2166 patients in 7 studies
and 5.9% (I2 = 93.71%, p < 0.001) among 3273 in 12 studies (Supple-
mentary Fig. 12).
3.4. Publication bias
Because publication bias could affect the results of meta-
analyses, we attempted to evaluate this potential publication bias
by using funnel plots analysis. Visualizing funnel plots for studies
evaluating the echocardiographic parameters suggested a symmet-7
ric distribution of studies around the effect size (Supplementary
Figs. 13–17).
4. Discussion
Percutaneous balloon mitral valvotomy (PMBV) is now deemed
as a preferable alternative to open mitral surgery in patients with
symptomatic moderate/severe MS with MVA  1.5 cm2, NYHA
functional class II-IV, favorable valve anatomy devoid of commis-
sural calcification, no or mild mitral regurgitation, and no LA
thrombus [11,12]. It is noteworthy that PMBV indications have
expanded to involve less suitable conditions including suboptimal
valve anatomy, and also as a palliative therapy in elderly patients
A.A. Abu Rmilah, M.A. Tahboub, A.K. Alkurashi et al. IJC Heart & Vasculature 33 (2021) 100765who are poor surgical candidates [13,14]. The main additive advan-
tage for offering PMBV to patients suffering from rheumatic mitral
stenosis must be its low cost in which the cost of mitral valve
replacement surgery is at least twice that of PMBV in the USA. Over
the years, PBMV has embraced as a mainstream therapy, especially
in developing countries with endemic rheumatic heart disease
[31,32].
Our present study is the first of its kind to review and statisti-
cally analyze the studies that assess the changes in the structural
and hemodynamic echocardiographic parameters occurring in
patients receiving PMBV for severe mitral stenosis. Our findings
suggest that successful PMBV leads to a significant increase in
MVA, LVEDP, LVEDV and decrease in MPG, LAP, LAD, and SPAP.
With growing experience, a considerable high success and low
complication rates in both short and long term follow-ups have
been documented in patients undergoing PMBV. The published
event-free survival rate at 10 years ranges from 70 to 90%
[13,15–19], however, the need for repeat PMBV or mitral valve sur-
gery, and the development post-PMBV severe MR, stroke, systemic
embolism and cardiac tamponade remain major concerns among
patients and providers alike despite the significant decrease in
the incidence of these events in the past few years. Our analysis
of more than 3500 patients has revealed that the pooled overall
incidence estimates of repeat PMBV, mitral valve surgery, post-
PMBV severe MR, and post-PMBV stroke, and
systemic thromboembolism, mortality on short term follow-up
(<30 days) were 0.5%, 2%, 1.4%, 0.4%, 0.7% and 0.2% respectively,
wherease on long term basis (> 6 months), the pooled overall inci-
dence estimates of the same aformentioned events were 5%, 11.5%,
5.5%, 2.7%, 1.7% and 5.9% respectively
Prediction of long term events including all-cause mortality,
mitral valve surgery, repeat PMBV, deterioration in NYHA func-
tional class  3 and major adverse cardiac and cerebrovascular
events (MACCE) has also been described. Multiple determinants
have been identified as independent predictors for these long term
outcomes. Chmielak et al. 2013 [16] evaluated the safety and effi-
cacy of PMBV for the treatment of MS in patients > 65y and found
that higher age and larger LAD before PMBV significantly predict
all-cause mortality. Another study published by Guilherme et al.
2019 [20] detected that post-PMV MPG, and lack of functional
improvement at 6-month follow-up are independent predictors
of aforementioned outcomes. Jorge et al. 2016 [17] prospectively
enrolled 532 patients who underwent PMBV from 1987 to 2011
and demonstrated that unfavorable valve anatomy; Wilkins
score > 8, post-PMV SPAP, and age appear to significantly antici-
pate the risk of adverse outcomes following PMBV. Two additional
studies consisting of 829 patients identified that AF, total echocar-
diographic score, immediate post-PMBV MVA < 1.8 cm2 could sig-
nificantly predict the occurrence of these outcomes on long term
basis [18,19].
Around 40% of all patients with RHD are estimated to have com-
bined MS and MR particularly patients with symptomatic severe
MS who have significantly concomitant moderate MR [3,21]. As
the co-existence of moderate MR is considered PMBV contraindica-
tion, mitral valve replacement surgery is the routine practice for
these patients thus exposing them to the risks of surgical compli-
cations, infective endocarditis and anticoagulation [3,21]. For that
reason, Desabandhu et al. 2016 [1] hypothesized that preserving
the native valve via PMBV could be a safe and effective alternative
measure that provides sustained symptomatic relief. Therefore,
they compared the safety and efficacy of PMBV in patients with
severe MS and moderate MR (group I, n = 17) with those with less
than moderate or no MR (group II, n = 208). Primary safety out-
come (defined as composite of cardiovascular death and develop-
ment of severe MR with or without requirement for mitral valve
replacement at 30 days of procedure) showed no significant differ-8
ence [2 (11.7%) in Group I vs. 8 (3.85%) in Group II, p = 0.36]; but
this may be due to small numbers of patients in Group I. A decline
in MR after PMBV has been described in few reports [14,22-26]
including Palacios et al. 1989 [24] who described three possible
mechanisms that could elucidate that decline, 1) reversible mitral
valve ‘‘stretching” by PMBV; 2) fibrosis and healing of the end of
the commissures, which may mitigate MR due to the excessive
splitting of the commissures; and 3) improvement in transient
papillary muscle dysfunction caused by balloon trauma at the time
of PMBV. However, for most patients, presence of preexisting mod-
erate mitral regurgitation must still be considered a contraindica-
tion to PMBV
The probability of AF development is high with an estimate of
40–70% in patients with MS, owing to the electrical heterogeneity,
and non-uniform conduction velocities as a result of left atrial
dilatation in response to valve obstruction and the inflammatory
and fibrotic changes caused by the rheumatic process [27]. AF
adversely causes blood stasis in the left atrial appendage, which
can precipitate thromboembolic complications such as ischemic
stroke [27]. Different success rates of the PMBV in patients with
AF and MS have been reported in previous studies. In a study
reported by Maatouk et al. 2005 [28], the immediate success rate
of the PMBV in 195 AF vs. 195 sinus rhythm SR patients was statis-
tically similar (89.7% vs. 92.3%, respectively). However, patients
with AF had a lower 10-year overall survival rate (91.4 versus
99.4%; p = 0.018), event-free-survival rate (60.3 versus 70%;
p = 0.02), and freedom from restenosis rate (40 versus 66%;
p = 0.048). On the other hand, Alsnabadi et al. 2016 [29] showed
that PMBV was successful in 554 (94.7%) of SR patients and 281
(67.7%) of AF patients (P < 0.001). Also, Nair et al. 2012 [30] indi-
cated a higher success rate of PMBV in SR patients (93.6% vs.
84.2%; P = 0.032).5. Limitations
Our review has some strengths and limitations. Strengths
included the comprehensive search strategy executed by profes-
sional librarian, and the process of the process of study screening,
data extraction and study quality assessment performed by two
independent reviewers. There are also some limitations in our
study. First, although comprehensive search strategies focused on
assessing the safety and efficacy of PMBV as well as its impact on
the structural and hemodynamic echocardiographic parameters
in patients with severe MS was implemented, this review is subject
to publication bias inevitably. Second, most of the included studies
are observational reports, which are of suboptimal quality and sub-
ject to selection bias. Third, our analysis was based on the data
from the studies published between 01/2012–10/2018 and thus
excluding many studies published prior to 2012 particularly those
reported by Vahanian et al. and Palacios et al. Fourth, most included
studies evaluated the acute changes in echocardiographic variables
within 24–72 h after the PMBV; therefore, further observational
studies are warranted to measure long-term effects of PMBV on
these variables. Finally, the heterogeneity between studies analyz-
ing echocardiographic parameters was statistically significant. We
believed that the observed heterogeneity in our meta-analysis was
mainly attributed to differences in population, study design,
follow-up, sample size or co-morbidities6. Conclusion
In conclusion, this is the first large international meta-analysis
of PMBV, and despite some heterogeneity in the data, there is
strong support for improvement in echocardiographic variables
including mitral valve area, mitral pressure gradient, left ventricu-
A.A. Abu Rmilah, M.A. Tahboub, A.K. Alkurashi et al. IJC Heart & Vasculature 33 (2021) 100765lar end-diastolic pressure and volume, pulmonary artery pressure
over 24–72 h following PMBV, and at an acceptably low rate of
complications including severe MR, stroke, systemic thromboem-
bolism, tamponade, and need for additional intervention (repeat
PMBV, mitral valve surgery) on the short (<30 days and long term
(>6 months) basis. Rheumatic heart disease continues to afflict
large numbers of people every year around the world and advance-
ment in measures for treatment and prevention of this condition
should remain a continuing goal.7. Research Funding
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